503A compounded
NAD+ Injection
Cellular energy, cognitive function, and systemic antiaging support.
Moderate evidence
Peptide therapy · immune modulator
Thymosin Alpha-1, immune modulation under physician supervision.
Thymosin Alpha-1 is a naturally occurring thymic peptide that helps regulate immune cell function. Its synthetic form is an approved drug in many countries for specific conditions, but it is not FDA-approved in the United States, where it is used as a compounded or research peptide. We frame it conservatively: the immune-modulating mechanism is well-characterized, the strongest human evidence is in defined clinical settings, and broad wellness claims are not established.
What it is
Thymosin Alpha-1 is a 28-amino-acid peptide identical to a fragment of prothymosin alpha, a protein produced by the thymus gland. The thymus is central to training and maturing T cells, and thymosin peptides participate in that immune-education process. Production of thymic peptides declines with age, which is part of the rationale for therapeutic interest.
Its synthetic form (thymalfasin, marketed in some countries as Zadaxin) is an approved medicine in roughly three dozen countries for indications such as chronic hepatitis B and C and as an immune adjuvant. It is not FDA-approved in the United States. In US practice it is supplied as a 503A compounded preparation or a research peptide, and the regulatory status of specific compounded peptides continues to evolve under ongoing FDA review.
We do not market Thymosin Alpha-1 as a treatment or cure for any infection, autoimmune condition, or cancer. It is offered, where appropriate, as an adjunctive immune-support therapy under provider supervision, with honest framing of what the evidence does and does not show.
How it works
T-cell modulation. Thymosin Alpha-1 supports the maturation and function of T cells and can shift the immune response toward a Th1 (cell-mediated) profile, which is relevant to antiviral and antitumor immunity.
Cytokine signaling. It has been shown to influence production of signaling molecules such as interleukin-2 and interferon-gamma, and to modulate dendritic cells, the immune system's antigen-presenting coordinators.
Toll-like receptor activity. Part of its effect is attributed to signaling through Toll-like receptors (notably TLR9 and TLR2), linking it to innate as well as adaptive immune pathways.
Restorative, not stimulatory in excess. The peptide is generally described as helping to normalize immune function rather than driving unchecked activation, which is consistent with its tolerability profile in approved-country use. Even so, its immune-modulating action is the reason for the cautions noted below.
Conditions and use cases
Where Thymosin Alpha-1 is studied and used.
- Immune adjuvant and support in defined clinical settings, where it is an approved medicine in some countries (off-label and not FDA-approved in the US).
- Adjunctive immune support during periods of higher demand or recovery, framed conservatively and individualized by a provider.
- Interest in immune resilience with age, based on the decline of thymic function over time. Human evidence for general longevity or wellness maintenance is limited.
- NOT positioned as: a treatment for any specific infection, an immune cure, or a substitute for vaccination, antivirals, or primary medical care.
Expected timeline
What patients commonly observe.
Week 0 to 2
Initiation and tolerability
Subcutaneous dosing begins after provider review. Generally well tolerated; effects are immune-modulating rather than immediately perceptible.
Week 2 to 6
Course-based use
Typically used in defined courses rather than indefinitely. Provider reviews response and rationale.
Month 2 to 3
Reassessment
Provider reassesses whether continued use is justified by the clinical context. No validated long-term wellness-maintenance schedule exists.
Ongoing
Periodic review
Because broad long-term wellness data are lacking, use is reviewed against goals and any change in health status, including autoimmune or transplant history.
Investment and access
Care plans, not menus.
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan tailored to your biology and goals.
Side effects
What patients commonly report.
Common. Injection site reactions such as redness, mild swelling, or discomfort. Thymosin Alpha-1 is generally well tolerated in approved-country clinical use.
Possible. Transient flu-like sensations or fatigue. As with any injectable peptide, sterile technique and a regulated compounding source matter.
Theoretical, mechanism-based. Because it modulates immune activity, there is a theoretical concern about aggravating autoimmune conditions or interfering with intentional immunosuppression, which informs the contraindications below.
Contraindications
Who should not use this therapy.
Show contraindications
Known hypersensitivity to thymosin alpha-1 or to compounding excipients.
Active autoimmune disease. Because the peptide enhances immune responses, use is approached with caution and provider oversight where autoimmunity is present.
Organ transplant recipients on immunosuppression. Stimulating immune function could theoretically counteract the intended immunosuppression; use is generally avoided.
Pregnancy and breastfeeding. Insufficient safety data; not used routinely.
Athletes. Confirm current sport-testing rules with your provider before starting any peptide. Thymosin Alpha-1 is an immune modulator and is distinct from thymosin beta-4 (TB-500).
Pairs well with
Therapies that complement this protocol.
- 503A compounded
Glutathione Injection
Antioxidant and detoxification support.
Moderate evidence - 503A compounded
Vitamin C Injection
Antioxidant support for immune health and skin radiance.
Moderate evidence
Frequently asked
Frequently asked questions about Thymosin Alpha-1.
No. Thymosin Alpha-1 (thymalfasin) is an approved medicine in many countries for specific indications, but it is not FDA-approved in the United States. In US practice it is supplied as a 503A compounded preparation or a research peptide, and the compounding status of specific peptides is subject to ongoing FDA review.
It is an immune-modulating peptide. It supports T-cell maturation and function, can shift immune responses toward a cell-mediated profile, and influences cytokine signaling and dendritic cells. The mechanism is well-characterized; the question is which clinical outcomes that mechanism reliably improves, which is where the evidence is stronger in defined indications and weaker for general wellness.
It has been studied as an immune adjuvant and in some infection settings, including observational reports in severe COVID-19, but the evidence is not definitive and it is not a treatment for any specific infection. We offer it as adjunctive support, never as a replacement for vaccination, antivirals, or medical care.
In approved-country clinical use it is generally well tolerated, with injection site reactions being most common. The main cautions are mechanism-based: active autoimmune disease and immunosuppressed transplant patients require careful provider judgment because the peptide modulates immune activity.
Typically as a subcutaneous injection in defined courses rather than indefinitely. Dosing and cadence are individualized by your provider after a Good Faith Exam and review of your health history.
Sources
Citations & references
- [1]King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016. Source
- [2]Camerini R, Garaci E. Historical review of thymosin alpha 1 in infection and cancer. Expert Opin Biol Ther. 2015. Source
- [3]Liu Y, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020 (observational). Source
- [4]FDA Human Drug Compounding overview (503A regulatory framework). Source
Status & disclosures
- FDA status: not FDA-approved in the US
- Thymosin Alpha-1 (thymalfasin) is approved in some countries but is not FDA-approved in the United States. Any US use is off-label and outside an FDA-approved drug product.
- 503A compounded / research peptide
- Supplied as a 503A compounded preparation or research peptide under U.S. regulations. The compounding eligibility of specific peptides continues to be reviewed by the FDA. Genesis sources from regulated compounders that follow USP standards.
- Mechanism-based cautions
- Because Thymosin Alpha-1 modulates immune function, it is used cautiously or avoided in active autoimmune disease and in transplant patients on immunosuppression. It is not offered as a treatment for any infection or disease.
Next step
Talk to a Genesis provider about Thymosin Alpha-1.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: Browse all therapy stacks